In our study, realization of these assays showed that our P. aeruginosa clinical strains are susceptible to various concentrations of AMK and TOB, two molecules considered as antimicrobials of first choice for treatment of pulmonary infections in CF. This evidence concerns the gene TOB1 and cystic fibrosis.